Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152

Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and raised the price target from $137 to $152. This adjustment reflects a positive outlook on the company's performance.